Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab extension study in hematologic malignancies
NCT06465433Phase 2Recruiting
- Sponsor
- Incyte
- Start
- Nov 2022
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of tafasitamab in hematologic malignancy, sponsored by Incyte. Started Nov 2022; status: recruiting.
02
Drugs
tafasitamab
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT06465433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06465433.